Oct-30-20 Reiterated
H.C. Wainwright
Buy
$47 → $55
Oct-08-20 Reiterated
H.C. Wainwright
Buy
$45 → $47
Oct-02-20 Reiterated
H.C. Wainwright
Buy
$40 → $45
Aug-05-20 Reiterated
H.C. Wainwright
Buy
$37 → $40
Jun-26-20 Initiated
BTIG Research
Buy
$40
Jun-19-20 Reiterated
H.C. Wainwright
Buy
$40 → $37
Oct-01-19 Resumed
Craig Hallum
Buy
$48
May-09-19 Upgrade
H.C. Wainwright
Neutral → Buy
$30 → $43
Feb-15-19 Initiated
Jefferies
Buy
$35
Oct-23-18 Resumed
Raymond James
Strong Buy
$30
Sep-18-18 Reiterated
H.C. Wainwright
Neutral
$17 → $22
Nov-27-17 Initiated
H.C. Wainwright
Buy
$12
Jun-14-16 Reiterated
Mizuho
Buy
$12 → $8
Sep-29-15 Downgrade
Raymond James
Outperform → Mkt Perform
Sep-25-15 Initiated
Craig Hallum
Buy
Mar-18-15 Reiterated
Mizuho
Buy
$15 → $12
Jan-25-21 04:28PM
Jan-20-21 10:56PM
Jan-19-21 05:11PM Investor's Business Daily +5.88%
04:14PM
11:19AM
Jan-11-21 07:00AM
Jan-08-21 07:01AM
07:00AM
Jan-07-21 07:00AM
Jan-04-21 07:00AM
Dec-31-20 07:10AM
Dec-30-20 12:00PM
08:53AM
Dec-23-20 07:29PM
Dec-22-20 09:59AM
Dec-21-20 07:06AM
Dec-18-20 11:22AM
Dec-17-20 10:30AM
Dec-14-20 12:00PM
Dec-01-20 07:00AM
Nov-26-20 12:00PM
Nov-25-20 07:00AM
Nov-17-20 05:00AM
Nov-14-20 08:00AM Investor's Business Daily
Nov-10-20 07:00AM
Nov-06-20 07:05AM
07:00AM
Oct-30-20 03:01PM
Oct-29-20 06:45PM
04:06PM
04:05PM
03:00PM
Oct-22-20 12:34PM
Oct-21-20 11:23AM
07:00AM
Oct-19-20 07:05AM
07:00AM
Oct-15-20 04:05PM
Oct-12-20 12:00PM
11:00AM
Oct-09-20 03:30AM
Oct-08-20 04:21PM
07:52AM
Oct-07-20 04:05PM
12:47PM
Oct-02-20 07:35AM
07:00AM
Sep-24-20 07:00AM
Sep-11-20 07:00AM
Sep-10-20 07:00AM
Sep-05-20 07:27AM
Sep-02-20 07:00AM
Aug-12-20 09:40AM
Aug-05-20 07:11AM
02:01AM
Aug-04-20 07:45PM
04:05PM
Jul-30-20 07:00AM
Jul-24-20 10:20PM
Jul-16-20 04:05PM
Jul-15-20 07:00AM
Jun-29-20 01:29PM Thomson Reuters StreetEvents +8.35%
Jun-24-20 04:12PM
Jun-22-20 07:00AM
Jun-18-20 04:05PM
07:00AM
Jun-15-20 04:05PM
Jun-10-20 08:12PM
Jun-09-20 05:13PM
08:00AM
Jun-08-20 05:00PM
Jun-04-20 07:00AM
May-28-20 07:00AM
May-27-20 07:00AM
May-15-20 07:00AM
May-14-20 08:15AM
May-07-20 07:00AM
May-05-20 07:00AM
May-02-20 08:35AM
May-01-20 01:00PM
Apr-30-20 04:05PM
Apr-27-20 07:00AM
Apr-23-20 12:32PM
07:00AM
Apr-22-20 07:00AM
Apr-21-20 07:00AM
Apr-14-20 07:00AM
Apr-09-20 07:00AM
Apr-08-20 04:01PM
Apr-06-20 07:00AM
Apr-02-20 06:44AM
Mar-25-20 12:46AM Thomson Reuters StreetEvents +13.21%
Mar-20-20 07:00AM
01:05AM
Mar-17-20 10:10AM
08:48AM
07:00AM
Mar-12-20 07:00AM
Mar-05-20 07:00AM
Feb-28-20 07:00AM
CareDx, Inc. discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss, as well as a partnership with IDbyDNA, Inc. for the development of metagenomic infectious disease testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SNYDERMAN RALPH Director Jan 15 Sale 88.88 12,000 1,066,513 72,672 Jan 19 08:58 AM King Sasha Chief Commercial Officer Jan 14 Option Exercise 9.20 9,875 90,866 53,306 Jan 15 05:21 PM King Sasha Chief Commercial Officer Jan 14 Sale 87.55 9,875 864,591 43,431 Jan 15 05:21 PM Cohen Fred E Director Jan 06 Option Exercise 14.74 15,000 221,100 105,893 Jan 06 08:37 PM Maag Peter Executive Chair Jan 05 Option Exercise 6.31 10,000 63,100 431,974 Jan 06 06:01 PM Maag Peter Executive Chair Jan 05 Sale 71.92 10,000 719,237 421,974 Jan 06 06:01 PM Seeto Reginald See Remarks Dec 18 Sale 68.01 8,363 568,801 114,035 Dec 18 08:40 PM Goldberg Michael Director Dec 14 Sale 70.19 30,000 2,105,722 57,404 Dec 14 07:57 PM Bickerstaff George Director Dec 14 Sale 71.76 10,000 717,644 80,487 Dec 14 07:50 PM Maag Peter Executive Chair Dec 07 Option Exercise 6.31 10,000 63,100 431,974 Dec 08 04:06 PM Maag Peter Executive Chair Dec 07 Sale 66.37 10,000 663,667 421,974 Dec 08 04:06 PM HAGSTROM WILLIAM A Director Nov 12 Option Exercise 6.50 10,000 65,000 28,575 Nov 13 04:08 PM HAGSTROM WILLIAM A Director Nov 12 Sale 54.59 10,000 545,888 18,575 Nov 13 04:08 PM Maag Peter Executive Chair Nov 05 Option Exercise 6.08 10,000 60,757 431,974 Nov 05 07:33 PM Maag Peter Executive Chair Nov 05 Sale 53.48 10,000 534,791 421,974 Nov 05 07:33 PM Bell Michael Brian Chief Financial Officer Nov 03 Option Exercise 16.75 25,640 429,549 135,917 Nov 03 07:42 PM Bell Michael Brian Chief Financial Officer Nov 03 Sale 48.15 32,574 1,568,487 103,343 Nov 03 07:42 PM King Sasha Chief Commercial Officer Oct 08 Option Exercise 9.38 25,779 241,732 84,206 Oct 09 05:03 PM King Sasha Chief Commercial Officer Oct 08 Sale 50.62 40,775 2,064,210 43,431 Oct 09 05:03 PM Maag Peter Chief Executive Officer Oct 05 Option Exercise 5.90 10,000 59,000 431,974 Oct 06 06:11 PM Maag Peter Chief Executive Officer Oct 05 Sale 42.11 10,000 421,128 421,974 Oct 06 06:11 PM Maag Peter Chief Executive Officer Oct 01 Option Exercise 5.67 20,000 113,351 441,974 Oct 02 06:26 PM Maag Peter Chief Executive Officer Oct 01 Sale 40.50 20,000 809,972 421,974 Oct 02 06:26 PM Maag Peter Chief Executive Officer Sep 30 Option Exercise 5.49 16,992 93,286 438,966 Sep 30 08:10 PM Maag Peter Chief Executive Officer Sep 30 Sale 37.59 16,992 638,802 421,974 Sep 30 08:10 PM Cohen Fred E Director Sep 21 Option Exercise 5.17 16,424 84,905 90,893 Sep 22 09:14 PM Maag Peter Chief Executive Officer Sep 08 Option Exercise 5.49 10,000 54,900 431,974 Sep 08 05:46 PM Maag Peter Chief Executive Officer Sep 08 Sale 31.68 9,900 313,609 422,074 Sep 08 05:46 PM Maag Peter Chief Executive Officer Aug 05 Option Exercise 5.32 13,008 69,247 434,982 Aug 07 05:56 PM Maag Peter Chief Executive Officer Aug 05 Sale 36.77 13,008 478,339 421,974 Aug 07 05:56 PM Maag Peter Chief Executive Officer Jul 06 Option Exercise 4.00 10,000 39,951 431,974 Jul 07 09:25 PM Maag Peter Chief Executive Officer Jul 06 Sale 34.21 10,000 342,098 421,974 Jul 07 09:25 PM Maag Peter Chief Executive Officer Jun 30 Option Exercise 2.30 9,267 21,314 400,156 Jul 02 05:40 PM Maag Peter Chief Executive Officer Jun 30 Sale 35.07 18,182 637,719 381,974 Jul 02 05:40 PM Maag Peter Chief Executive Officer Jun 09 Sale 35.00 1,818 63,630 389,499 Jun 11 07:44 PM Maag Peter Chief Executive Officer Jun 05 Sale 32.58 50,000 1,629,167 391,317 Jun 05 07:47 PM King Sasha Chief Commercial Officer Jun 01 Sale 33.10 25,402 840,839 28,334 Jun 01 07:21 PM Maag Peter Chief Executive Officer May 19 Sale 32.24 30,000 967,122 459,909 May 19 06:16 PM Bickerstaff George Director May 13 Sale 27.65 10,000 276,458 85,657 May 13 05:28 PM Goldberg Michael Director May 11 Sale 29.86 10,000 298,628 80,765 May 11 07:05 PM HAGSTROM WILLIAM A Director May 06 Option Exercise 1.22 15,000 18,300 30,385 May 07 07:29 PM Bell Michael Brian Chief Financial Officer May 06 Option Exercise 6.57 35,816 235,189 134,229 May 08 07:18 PM HAGSTROM WILLIAM A Director May 06 Sale 29.12 15,000 436,829 15,385 May 07 07:29 PM Bell Michael Brian Chief Financial Officer May 06 Sale 29.00 57,136 1,657,032 77,093 May 08 07:18 PM Maag Peter Chief Executive Officer Mar 16 Sale 17.39 10,000 173,873 489,909 Mar 16 08:48 PM SNYDERMAN RALPH Director Mar 03 Option Exercise 3.70 14,598 53,998 79,901 Mar 04 08:37 PM Maag Peter Chief Executive Officer Feb 18 Sale 26.62 10,000 266,201 451,909 Feb 19 07:25 PM King Sasha Chief Commercial Officer Feb 14 Sale 26.01 7,390 192,221 48,502 Feb 14 09:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite